Acacia’s Barhemsys (amisulpride) Receives the US FDA’s Approval for the Prevention of Postoperative Nausea and Vomiting

 Acacia’s Barhemsys (amisulpride) Receives the US FDA’s Approval for the Prevention of Postoperative Nausea and Vomiting

Acacia’s Barhemsys (amisulpride) Receives the US FDA’s Approval for the Prevention of Postoperative Nausea and Vomiting

Shots:

  • Barhemsys is the first and only antiemetic to be approved for the rescue treatment of PONV in patients who have failed standard prophylaxis with its anticipated launch in H2’20
  • The results of the clinical program showed that Barhemsys (10mg) is significantly more effective compare to PBO (42% vs 29%) while in another study Barhemsys (5mg) + other antiemetics vs PBO demonstrated improvement in protection from PONV (58% vs 47%)
  • Barhemsys is an IV formulation of the selective dopamine D2 and D3 antagonist amisulpride (2.5 mg/mL). Additionally, Acacia’s Byfavo (remimazolam injection) is currently under FDA’s review for use in procedural sedation in adult with its anticipated PDUFA as Apr 05,2020

Click here to read full press release/ article | Ref: Acaia | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post